BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 9345340)

  • 1. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
    Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
    Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
    Bensmaine M el-A ; Guillot T; Bernal ET; Janot F; Sigal R; Domenge C; Wibault P; Armand JP; Cvitkovic E
    Am J Clin Oncol; 1996 Aug; 19(4):356-62. PubMed ID: 8677904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
    Alba E; Sanchez-Chaparro MA; Alonso L; Ribelles N; Ramon Delgado J; Rueda A; Pablo Tenllado P; Solano J; Urquiza R
    Am J Clin Oncol; 1996 Apr; 19(2):140-3. PubMed ID: 8610637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
    Kish JA; Wolf MK; Schellhammer PF; Hussain MH; Einstein AB; Crawford ED
    Am J Clin Oncol; 1997 Aug; 20(4):327-30. PubMed ID: 9256883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    Riva C; Lavieille JP; Schmerber S; Cuisnie O; Reyt E
    Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
    Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
    Tellez-Bernal E; Belehradek M; Recondo G; Cvitkovic E; Leridant AM; Vericel R; Armand JP
    Am J Clin Oncol; 1990 Oct; 13(5):452-4. PubMed ID: 1699403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F; Comella P; Marcolin P; Russo Spena F; Biglietto M; Cartenì G; De Lucia L; Avallone A; Gravina A; Comella G
    Cancer; 1999 Feb; 85(4):952-9. PubMed ID: 10091775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
    Kohno N; Ichikawa G; Shirasaka T; Inuyama Y; Kawaida M; Ohnuma T
    Gan To Kagaku Ryoho; 1995 Aug; 22 Suppl 3():209-14. PubMed ID: 7661582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
    Kucuk O; Shevrin DH; Pandya KJ; Bonomi PD
    Am J Clin Oncol; 2000 Aug; 23(4):371-5. PubMed ID: 10955866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
    Kohno N; Kitahara S; Tamura E; Tanabe T
    Oncology; 2002; 63(3):226-31. PubMed ID: 12381901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
    Faivre C; Rougier P; Ducreux M; Mitry E; Lusinchi A; Lasser P; Elias D; Eschwege F
    Bull Cancer; 1999 Oct; 86(10):861-5. PubMed ID: 10572237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
    Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
    Amrein PC; Fabian RL
    Laryngoscope; 1992 Aug; 102(8):901-6. PubMed ID: 1379664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
    Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
    Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
    Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
    Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.